Recombinant Human Siglec-9 Protein, Fc Tag, 100 µg

Background
siglec-9 (HGMW-approved symbol SIGLEC9) a member of the sialic acid-binding Ig-like lectin (Siglec) family, which belongs to the immunoglobulin superfamily (IgSF). SIGLEC9 shows a high degree of homology to many members of the siglec family, including siglec-7 (80%), siglec-8 (72%), siglec-5 (65%), and CD33 (64%). This high degree of homology is also conserved in the extracellular Ig-like domains. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by varying numbers of Ig-like C2-type domains。Siglec-9 with a hydrophobic signal peptide, an N-terminal Ig-likeV-type domain, two Ig-like C2-type domains, a transmembrane region and a cytoplasmic tail.

Source
Recombinant Human Siglec-9, Fc Tag (SI9-H5256) is expressed from human 293 cells (HEK293). It contains AA Gln 18 - Gly 348 (Accession # Q9Y336-1).
Predicted N-terminus: Gln 18

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 62.5 kDa. The protein migrates as 80-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1)  "90 K increased delivery efficiency of extracellular vesicles through mediating internalization"
Zhu, Yang, Wei et al
J Control Release (2022) 353, 930-942
(2)  "Development of Effective Siglec-9 Antibodies Against Cancer"
Wang, Jiang, Jain et al
Curr Oncol Rep (2022)
(3)  "Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity"
Huang, Li, Mei et al
J Transl Med (2022) 20 (1), 496
Showing 1-3 of 159 papers.